Biology:Vasopressin receptor 2
![]() Generic protein structure example |
Vasopressin receptor 2 (V2R), or arginine vasopressin receptor 2 (officially called AVPR2), is a protein that acts as receptor for vasopressin.[1] AVPR2 belongs to the subfamily of G-protein-coupled receptors. Its activity is mediated by the Gs type of G proteins, which stimulate adenylate cyclase.
AVPR2 is expressed in the kidney tubule, predominantly in the membrane of cells of the distal convoluted tubule and collecting ducts, in fetal lung tissue and lung cancer, the last two being associated with alternative splicing. AVPR2 is also expressed outside the kidney in vascular endothelium.[2] Stimulation causes the release of von Willebrand factor and factor VIII from the endothelial cells.[2] Because von Willebrand factor helps stabilize circulating levels of factor VIII, the vasopressin analog desmopressin can be used to stimulate the AVPR2 receptor and increase levels of circulating factor VIII. This is useful in the treatment of hemophilia A as well as Von Willebrand disease.
In the kidney, AVPR2's primary property is to respond to arginine vasopressin by stimulating mechanisms that concentrate the urine and maintain water homeostasis in the organism. When the function of AVPR2 is lost, the disease nephrogenic diabetes insipidus (NDI) results.
Antagonists
Vasopressin receptor antagonists that are selective for the V2 receptor include:
- Tolvaptan (FDA-approved)
- Lixivaptan
- Mozavaptan
- Satavaptan
Their main uses are in hyponatremia, such as that caused by syndrome of inappropriate antidiuretic hormone (SIADH) and heart failure, however these agents should be avoided in patients with cirrhosis.[3]
Demeclocycline and lithium carbonate act as indirect antagonists of renal vasopressin V2 receptors by inhibiting activation of the second messenger cascade of the receptors.[4][5]
Pharmacoperones
Vasopressin receptor 2 function has been shown to be deleteriously effected by point mutations in its gene. Some of these mutations, when expressed, cause the receptor to remain in the cytosol. An approach to rescue receptor function utilizes pharmacoperones or molecular chaperones, which are typically small molecules that rescue misfolded proteins to the cell surface. These interact with the receptor to restore cognate receptor function devoid of antagonist or agonist activity. This approach, when effective, should increase therapeutic reach. Pharmacoperones have been identified that restore function of V2R.[6][7][8][9]
Interactions
Arginine vasopressin receptor 2 has been shown to interact with C1QTNF1.[10]
References
- ↑ "Colocalization of the gene for nephrogenic diabetes insipidus (DIR) and the vasopressin type 2 receptor gene (AVPR2) in the Xq28 region". Genomics 13 (4): 1350–2. Aug 1992. doi:10.1016/0888-7543(92)90067-3. PMID 1324225.
- ↑ 2.0 2.1 Jackson EK (2018). "Drugs Affecting Renal Excretory Function". In: Brunton LL, Hilal-Dandan R, Knollmann BC. eds. Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 13e New York, NY: McGraw-Hill.
- ↑ "SAMSCA (tolvaptan) prescribing information". US Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022275s007lbl.pdf.
- ↑ Ajay K. Singh; Gordon H. Williams (12 January 2009). Textbook of Nephro-Endocrinology. Academic Press. pp. 250–251. ISBN 978-0-08-092046-7. https://books.google.com/books?id=TsbV_KMn4yAC&pg=PA250.
- ↑ L. Kovács; B. Lichardus (6 December 2012). Vasopressin: Disturbed Secretion and Its Effects. Springer Science & Business Media. pp. 179–180. ISBN 978-94-009-0449-1. https://books.google.com/books?id=UQztCAAAQBAJ&pg=PA179.
- ↑ "Chemical validation and optimization of pharmacoperones targeting vasopressin type 2 receptor mutant". Biochemical Journal 475 (18): 2941–2953. September 2018. doi:10.1042/BCJ20180065. PMID 30068530.
- ↑ "Receptor antagonism/agonism can be uncoupled from pharmacoperone activity". Molecular and Cellular Endocrinology 434: 176–185. October 2016. doi:10.1016/j.mce.2016.07.003. PMID 27389877.
- ↑ "Identification of Potential Pharmacoperones Capable of Rescuing the Functionality of Misfolded Vasopressin 2 Receptor Involved in Nephrogenic Diabetes Insipidus". SLAS Discovery 21 (8): 824–831. September 2016. doi:10.1177/1087057116653925. PMID 27280550.
- ↑ "High-throughput screen for pharmacoperones of the vasopressin type 2 receptor". SLAS Discovery 18 (8): 930–937. September 2013. doi:10.1177/1087057113483559. PMID 23640875.
- ↑ "GIP, a G-protein-coupled receptor interacting protein". Regulatory Peptides 109 (1–3): 173–9. Nov 2002. doi:10.1016/S0167-0115(02)00201-X. PMID 12409230.
Further reading
- "The V2 vasopressin receptor mutations and fluid homeostasis". Cardiovascular Research 51 (3): 409–15. Aug 2001. doi:10.1016/S0008-6363(01)00337-6. PMID 11476731.
- "[Nephrogenic diabetes insipidus associated with mutations of vasopressin V2 receptors and aquaporin-2]". Nihon Rinsho. Japanese Journal of Clinical Medicine 60 (2): 350–5. Feb 2002. PMID 11857925.
- "Chapter 14 Molecular pharmacology and modeling of vasopressin receptors". Vasopressin and Oxytocin: From Genes to Clinical Applications. Progress in Brain Research. 139. 2002. pp. 179–96. doi:10.1016/S0079-6123(02)39016-2. ISBN 9780444509826.
- "Nephrogenic diabetes insipidus". Advances in Chronic Kidney Disease 13 (2): 96–104. Apr 2006. doi:10.1053/j.ackd.2006.01.006. PMID 16580609. http://discovery.ucl.ac.uk/1540833/.
- "Cell biological aspects of the vasopressin type-2 receptor and aquaporin 2 water channel in nephrogenic diabetes insipidus". American Journal of Physiology. Renal Physiology 291 (2): F257–70. Aug 2006. doi:10.1152/ajprenal.00491.2005. PMID 16825342. https://repository.ubn.ru.nl/bitstream/2066/50267/1/50267.pdf.
- "Mutations in the V2 vasopressin receptor gene are associated with X-linked nephrogenic diabetes insipidus". Nature Genetics 2 (2): 103–6. Oct 1992. doi:10.1038/ng1092-103. PMID 1303257.
- "Mutations in the vasopressin type 2 receptor gene (AVPR2) associated with nephrogenic diabetes insipidus". Nature Genetics 2 (2): 99–102. Oct 1992. doi:10.1038/ng1092-99. PMID 1303271.
- "Colocalization of the gene for nephrogenic diabetes insipidus (DIR) and the vasopressin type 2 receptor gene (AVPR2) in the Xq28 region". Genomics 13 (4): 1350–2. Aug 1992. doi:10.1016/0888-7543(92)90067-3. PMID 1324225.
- "Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus". Nature 359 (6392): 233–5. Sep 1992. doi:10.1038/359233a0. PMID 1356229. Bibcode: 1992Natur.359..233R.
- "Structure and chromosomal localization of the human antidiuretic hormone receptor gene". American Journal of Human Genetics 51 (5): 1078–83. Nov 1992. PMID 1415251.
- "Molecular cloning of the receptor for human antidiuretic hormone". Nature 357 (6376): 333–5. May 1992. doi:10.1038/357333a0. PMID 1534149. Bibcode: 1992Natur.357..333B.
- "Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus". Nature 357 (6376): 336–9. May 1992. doi:10.1038/357336a0. PMID 1534150. Bibcode: 1992Natur.357..336L.
- "Three-point linkage analysis using multiple DNA polymorphic markers in families with X-linked nephrogenic diabetes insipidus". Genomics 4 (3): 434–7. Apr 1989. doi:10.1016/0888-7543(89)90352-2. PMID 2714800.
- "Binding-, intracellular transport-, and biosynthesis-defective mutants of vasopressin type 2 receptor in patients with X-linked nephrogenic diabetes insipidus". The Journal of Clinical Investigation 96 (4): 2043–50. Oct 1995. doi:10.1172/JCI118252. PMID 7560098.
- "Mutations in the vasopressin V2-receptor gene in three families of Italian descent with nephrogenic diabetes insipidus". Human Molecular Genetics 3 (9): 1685–6. Sep 1994. doi:10.1093/hmg/3.9.1685. PMID 7833930.
- "An extracellular congenital nephrogenic diabetes insipidus mutation of the vasopressin receptor reduces cell surface expression, affinity for ligand, and coupling to the Gs/adenylyl cyclase system". Molecular Endocrinology 8 (7): 886–94. Jul 1994. doi:10.1210/mend.8.7.7984150. PMID 7984150.
- "Novel mutations in the V2 vasopressin receptor gene of patients with X-linked nephrogenic diabetes insipidus". Human Molecular Genetics 3 (8): 1429–30. Aug 1994. doi:10.1093/hmg/3.8.1429. PMID 7987330.
- "Two novel mutations in the vasopressin V2 receptor gene in patients with congenital nephrogenic diabetes insipidus". Biochemical and Biophysical Research Communications 205 (1): 552–7. Nov 1994. doi:10.1006/bbrc.1994.2700. PMID 7999078.
- "Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insipidus". American Journal of Human Genetics 55 (2): 278–86. Aug 1994. PMID 8037205.
- "Novel mutations in the V2 vasopressin receptor gene in two pedigrees with congenital nephrogenic diabetes insipidus". The Journal of Clinical Endocrinology and Metabolism 79 (2): 361–5. Aug 1994. doi:10.1210/jcem.79.2.8045948. PMID 8045948.
External links
- GeneReviews/NCBI/NIH/UW entry on Nephrogenic Diabetes Insipidus
- "Symbol Report: AVPR2". HUGO Gene Nomenclature Committee (HGNC). https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/897.
- "Vasopressin and Oxytocin Receptors: V2". International Union of Basic and Clinical Pharmacology. http://www.iuphar-db.org/GPCR/ReceptorDisplayForward?receptorID=2964.
- Human AVPR2 genome location and AVPR2 gene details page in the UCSC Genome Browser.
- Overview of all the structural information available in the PDB for UniProt: P30518 (Vasopressin V2 receptor) at the PDBe-KB.
![]() | Original source: https://en.wikipedia.org/wiki/Vasopressin receptor 2.
Read more |